



JP Morgan Healthcare Conference Summary

January 2022 (January 10th-13th)



Confidential & Privileged

J.P. Morgan 2022 – Schedule

Jan 10th



Jan 11th



Jan 12th



Jan 13th





Dermatology



Gastroenterology



Rheumatology

Key Takeaways

Company	Key Monitoring Topics	Notes/Takeaways	Why Important
 InflaRx	<ul style="list-style-type: none"> Details about newly registered vilobelimab (C5a inhibitor) trial in HS Potential timelines for trial initiation Trial set-up, patient inclusion (mod-severe) Any more details on FDA recommendation on modified HiSCR versus traditional HiSCR IFX-2 (advancement to Vilobelimab in early dev, also a C5a) – what are the ongoing pre-clinical activities and timelines? Hint on indications to be followed? 	<ul style="list-style-type: none"> InflaRx will begin enrolling its phase 3 trial of vilobelimab in HS soon, and will be using a novel primary endpoint. New oral C5aR inhibitor, INF904, set to enter clinic in H2 2022. 	<ul style="list-style-type: none"> Introduction of a novel endpoint could change the game in HS moving forward. While FDA seems signed off, it will be critical to understand what other regulators think of the modified HiSCR. It is unclear also how physicians will view the modified HiSCR.
 Kymera	<ul style="list-style-type: none"> IRAK4 (KT-474) in Ph1 development in Multiple Immuno-inflammatory Diseases: HS, AD, RA, others Any update given on IRAK4? STAT3 in discovery phase in autoimmune and fibrotic diseases Any update? 	<ul style="list-style-type: none"> Kymera (with Sanofi) will be advancing KT-474 (IRAK4) into phase 2 for RA, HS, and AD in 2022. 	<ul style="list-style-type: none"> IRAK4 is becoming a more common mechanism being pursued in dermatology. Multiple IRAK4 assets will be competing in the space so it will be important to understand how they differ from each other.
 Lilly	<ul style="list-style-type: none"> Likely to hear about lebrizumab in AD with recent release of positive topline data from pivotal trials How will it be differentiating against dupixent? Any impact by JAKs safety warning? Updates on Mirikizumab and when to expect data (have expectations for early 2022 for UC maintenance) Opportunity for differentiation? 	<ul style="list-style-type: none"> Lilly expects mirikizumab to be the first IL-23 in the UC market. No updates on JAK safety or on lebrizumab. 	<ul style="list-style-type: none"> Lilly has done a decent job of navigating mirikizumab away from a saturated indication like psoriasis and toward an area that has a much greater need and less on-market competition in IBD. This shows that Lilly is willing to adjust strategies in order to get its products onto the market as soon as possible.



Dermatology



Gastroenterology



Rheumatology

Key Takeaways

Company	Key Monitoring Topics	Notes/Takeaways	Why Important
	<ul style="list-style-type: none"> Information on Kadmon acquisition asset, belumosudil, and its development plans in SSc 	<ul style="list-style-type: none"> Sanofi believes it is possible to file amlitelimab (anti-OX40) in AD before the end of 2024 	<ul style="list-style-type: none"> With competition ramping up for Dupixent, there is more emphasis on Sanofi pipeline competitors.
	<ul style="list-style-type: none"> Updates on Entyvio SC in IBD and FDA requirements for device. 	<ul style="list-style-type: none"> SC formulation is still expected, but no specified date provided. 	<ul style="list-style-type: none"> The FDA has scrutinized novel injection devices over the past few years. Understanding what criteria the FDA and other regulatory agencies use for new devices will help to guide appropriate clinical trials/bridging studies.
	<ul style="list-style-type: none"> FDA deferred action on Oct PDUFA for Bimzelx (bimekizumab) due to inspection delays, likely to hear update on application as well as more details on recent topline data in ax-SpA and PsA 	<ul style="list-style-type: none"> Bimekizumab launch in the US is expected in 2Q22 (PsO) UCB's strategy for bimekizumab is having differentiation with real prescription value, and having rebates is less important. Bimekizumab Phase 3 readout for HS has changed slightly to 2H22 (originally expected in 3Q22) 	<ul style="list-style-type: none"> Bimzelx should immediately hit the ground running and will be a serious competitor in the psoriasis space, as well as its other pipeline indications.

Release Slides

Summary of Inflammation

- ChemoCentryx focused on Tavneos launch in ANCA vasculitis as well as expanding Tavneos into other indications including HS.
 - Although the company noted that C3G and LN were high priority indications.
- ChemoCentryx also heavily focused on asset, CCX559, a PD-1/PD-L1 inhibitor that is being developed for oncology.

Key Details from Company Presentation

Tavneos/avacopan (C5a inhibitor)

- First commercially available medicine from ChemoCentryx
- Currently in ph2 for C3 glomerulopathy and **severe HS, in ph1 for LN**
- **Plans to meet with FDA to advance into ph3 development for HS**
 - **Ph3 HS trial will be a two-arm trial with 300-400 subjects, primary endpoint will be HiSCR or similar at 12 weeks, open-label follow-up period**
- **Plans to meet with FDA to initiate LN study**

Vercirnon (CCR9 antagonist)

- Pipeline shows CCX507 (CCR9) is in ph1 for UC
- No mention of Vercirnon

Top Takeaways/Impact

ChemoCentryx is planning to meet with the FDA to discuss Tavneos/avacopan phase 3 trial in HS, which is expected to start in 2022.

Why Important:
ChemoCentryx and InflaRx both have C5a inhibitors entering phase 3 trials for HS.

Relevant Catalysts mentioned at JPM

Tavneos/avacopan (C5a inhibitor)		
HS	2Q22	Meet with FDA for ph3 development
HS	2022	Phase 3 trial start
LN	2Q22	Meet with FDA for clinical trial initiation
LN	2022	Clinical trial start

Analyst Q&A

- No relevant Q&A

Next Steps for TAVNEOS 2022

Hidradenitis Suppurativa

- Meet with FDA in Q2; advance into Phase III development in Hurley Stage 3 (severe) thereafter (2022 start)
- Approximately 30-50K Hurley III patients in US
- Phase III: Two-arm trial; ~300-400 subjects total; HiSCR or similar endpoint at 12 weeks; open-label follow up period

Lupus Nephritis

- Meet with FDA Q2; initiate study after feedback (2022 start)
- Goal of plan is to the most efficient path to registration and what is required

C3 Glomerulopathy

- Discuss evidence of clinical benefit in C3G (ACCOLADE trial) with FDA in mid 2022



Summary of Inflammation

- Kymera spent the first half of its presentation discussing its scientific approach and platform; the company's goal is to become a disease agnostic biopharma company utilizing targeted protein degradation technology.
- The presentation focused on KT-474 (IRAK4i), KT-333, KT-413, and KT-253 assets with KT-474 being the only one being developed for autoimmune indications.
- No updates for STAT3 discovery for autoimmune indications

Key Details from Company Presentation

KT-474 (IRAK4i)

- Best in class potential. Overview of Phase 1 trial that included healthy volunteers (HV) as well as AD and HS patients (up to 20 combined) in MAD portion of the study. First portions of the study were SAD/MAD in HV
- Could potentially be developed for AD, HS, RA, SLE, IBD, Gout, PsO, Asthma, COPD, CRSwNP
 - **AD, HS, and RA** highlighted as key areas for development

Top Takeaways/ Impact

Kymera (with Sanofi) will be advancing KT-474 into phase 2 for RA, HS, and AD in 2022.

Why Important:

IRAK4 is becoming a more common mechanism being pursued in dermatology. Multiple IRAK4 assets will be competing across these indication, so it will be important to understand how they differ from each other.


Relevant Catalysts mentioned at JPM

KT-474 (IRAK4i)

AD/HS	1Q22	Initiate open-label Phase 1 for AD and HS
AD/HS	2H22	Phase 1 data in AD/HS patients expected
AD/HS/RA	2022	Initiation of Phase 2

Analyst Q&A

- **No relevant questions asked**



Monday – Important Topics



Dermatology



Gastroenterology



Rheumatology

Monday 10th

BMS



Gilead



Horizon



Janssen / J&J



Novartis



Pfizer



Regeneron



Takeda



BMS

- Update to deucravacitinib's approval timeline in PsO, perhaps details about approval in Japan for PsO
- Likely an update on Zeposia's progress in uptake in UC
- Any update on Nimbus gaining full rights again on their TYK2

Gilead

- Any information on if Gilead will pursue filgotinib in U.S. for UC
- Update on future goals for Gilead/Galapagos partnership in inflammation

Horizon

- Tepezza (teprotumumab, anti-IGF-1R) is also being studied in dSSc (Ph1), SC formulation in Ph1
- HZN1116 mAB in Ph1 development in autoimmune diseases – which indications? Which mAB?

Janssen / J&J

- Likely to update on Tremfya progress/timeline in IBD
- Further data on bermekimab (IL1a) – Ph2b

Novartis

- Any information on Cosentyx Ph 3 HS data and regulatory timeline

Pfizer

- Recently announced acquisition of Arena, likely to hear more about it, as well as perhaps more about company that Pfizer recently licensed brepocitinib (TYK2/JAK1) and PF-06826647 (TYK2) candidates to unnamed company
- Update on Abrocitinib application for AD in US
 - Abrocitinib differentiation to Dupixent?
- Any update on IRAK4 development (currently in Ph2)

Regeneron

- Likely to give updates on Dupixent franchise, especially considering the launches of recent competitors (anti-IL13 and JAKs)

Takeda

- Updates on Entyvio SC in IBD and FDA requirements for device.

Tuesday – Important Topics



Dermatology



Gastroenterology



Rheumatology

Tuesday 11th

AbbVie



Almirall



Amgen



Lilly



Roche



Sanofi



Kymera Tx



Protagonist



AbbVie

- Updates on Rinvoq applications/approval timeline in AD (U.S.), filing for CD
- Skyrizi in IBD application/timeline updates
- Any information on Lutikizumab and HS trial

Almirall

- Likely to touch on recent lebrikizumab positive Ph 3 data in AD

Amgen

- Likely to also discuss Otezla's recent label expansion into mild PsO as well as topline results from trial in genital PsO

Lilly

- Likely to hear about lebrikizumab in AD with recent release of positive topline data from pivotal trials
 - How will it be differentiating against dupixent?
 - Any impact by JAKs safety warning?
- Updates on Mirikizumab and when to expect data (have expectations for early 2022 for UC maintenance)
 - Opportunity for differentiation?

Roche

- Any updates on etrolizumab (anti-A4 β 7) in CD (awaiting Ph 3 data)

Sanofi

- Information on Kadmon acquisition asset, belumosudil, and its development plans in SSx

Kymera Tx

- IRAK4 (KT-474) in Ph1 development in Multiple Immuno-inflammatory Diseases: HS, AD, RA, others
 - Any update given on IRAK4?
- STAT3 in discovery phase in autoimmune and fibrotic diseases
 - any update?

Protagonist Therapeutics

- Oral IL23R (PN235) in development in collaboration with Janssen
- Ph2 initiation planned in Psoriasis and IBD in 2022 – any news on this?

Wednesday – Important Topics

Wednesday
12th

ChemoCentryx  

UCB   

ChemoCentryx

- Updates on Avacopan (C5a inhibitor) Ph 2 HS trial, any regulatory update
- Any information on possible Ph 3 trial in HS
- Vercirnon -CCR9 antagonist – Ph3 ready in mod-sev CD, any developments there? Partnering?

UCB

- FDA deferred action on Oct PDUFA for Bimzelx (bimekizumab) due to inspection delays, likely to hear update on application as well as more details on recent topline data in ax-SpA and PsA
- Potential news on further strategy

Thursday – Important Topics potentially discussed

Thursday
13th

Aurinia 

Galapagos   

InflaRx 

Aurinia

- Further details about pipeline candidates AUR200 (anti-BAFF/APRIL) and AUR300 (macrophage modulator) being developed for autoimmune and fibrotic conditions
- Likely to discuss Lupkynis (voclosporin) which was recently approved for LN and timeline for SLE
- Any news on Aurinia buyout rumors

Galapagos

- Any update of GLPG4716 in IPF (preparing for Ph2)
- Will likely discuss details of Jyseleca (Filgotinib, JAK) UC label expansion in EU
- TYK2 GLPG3667 PsO study update (dose finding)?
- Any further news from the TOLEDO program?

InflaRx

- Details about newly registered vilobelimab (C5a inhibitor) trial in HS
 - Potential timelines for trial initiation
 - Trial set-up, patient inclusion (mod-severe)
 - Any more details on FDA recommendation on modified HiSCR versus traditional HiSCR
- IFX-2 (advancement to Vilobelimab in early dev, also a C5a) – what are the ongoing pre-clinical activities and timelines?
 - Hint on indications to be followed?

Full agenda – Day 1 (Monday)

MONDAY, JANUARY 10 CONFERENCE AGENDA (as of 12.31.2021, subject to change)

*All sessions are Eastern Time

Eastern Time	TRACK 1	TRACK 2	TRACK 3	TRACK 4	TRACK 5	TRACK 6	TRACK 7	TRACK 8	TRACK 9	NOT FOR PROFIT
7:15 AM	Opening Remarks: Mike Gaito, Global Head of Healthcare Investment Banking, J.P. Morgan									
7:30 AM	Bristol-Myers Squibb Co.	CENTENE Corporation	Incyte	Catalent	PTC Therapeutics, Inc.	Intra-Cellular Therapies Inc	AtriCure Inc	Replimune	argenx	AdventHealth
8:15 AM	Royalty Pharma plc	Novartis	Moderna	Waters Corporation	Atea Pharmaceuticals	Emergent BioSolutions, Inc.	Medtronic	Apellis Pharmaceuticals Inc	Fresenius SE & Co.KG&A	Henry Ford Health System
9:00 AM	Coherus BioSciences, Inc.	Teladoc Health	Vertex Pharmaceuticals	Bruker Corporation	Novavax Inc.	Deciphera Pharmaceuticals, Inc.	CONMED Corporation	Zai Lab Ltd	SYNLAB	Advocate Aurora Health
9:45 AM	Johnson & Johnson	Agilon Health	Biogen	Avantor	TG Therapeutics Inc	BioCryst Pharmaceuticals, Inc.	Baxter International Inc.	Alynham Pharmaceuticals, Inc.	Bayer	Intermountain Healthcare
10:30 AM	Passage Bio	Cardinal Health, Inc.	Regeneron Pharmaceuticals, Inc.	Absci	C4 Therapeutics, Inc.	Halozyme Therapeutics, Inc.	Dexcom Inc	Sarepta Therapeutics, Inc.	Sonova	Ascension
11:15 AM	Horizon Therapeutics	West Pharmaceutical Services Inc.	Gilead Sciences Inc.	Seer, Inc.	Recursion Pharmaceuticals, Inc.	Cara Therapeutics	Edwards Lifesciences Corp.	Neurocrine Biosciences Inc.	RI RCM Inc.	CommonSpirit Health
12:00 – 12:30 PM	BREAK								New Generation of Public & Popul. Health**	BREAK
12:30 – 1:25 PM	Keynote: Jamie Dimon, Chairman and Chief Executive Officer, JPMorgan Chase & Co. Interviewed by: Jessica Fye, Managing Director, Equity Research- Biotech, J.P. Morgan									
1:30 PM	Zoetis, Inc.	Hyperfine, Inc	BioMarin Pharmaceuticals	QIAGEN N.V.	Rocket Pharmaceuticals Inc	Edgewise Therapeutics, Inc.	ResMed	Kiniksa Pharmaceuticals, Ltd.	H. Lundbeck	Baylor Scott & White Health
2:15 PM	Organon	Oak Street Health, Inc.	Cerevel Therapeutics	10x Genomics	Beam Therapeutics, Inc.	Jazz Pharmaceuticals plc	Roivant Sciences	Kodiak Sciences Inc.	TBD	Children's Hospital of Philadelphia
3:00 PM	Pfizer	Privia Health Group, Inc.	Seagen Inc.	Guardant Health, Inc.	Envista Holdings Corporation	Ascendis Pharma	Zimmer Biomet Holdings, Inc.	BridgeBio Pharma	Pacira Biosciences	University of Maryland Medical System
3:45 PM	EQRx	Humana Inc	Ultragenyx Pharmaceutical Inc.	Adaptive Biotechnologies	Illumina, Inc	Insmed	Phreesia	Erasca, Inc.	Summit Therapeutics	Children's National Hospital
4:30 PM	Nevro	Amerisource Bergen Corp.	Takeda Pharmaceutical Company Limited	Twist Bioscience Corporation	Natera	Stoke Therapeutics	Verve Therapeutics	Allovir, Inc.	Sema4	Oregon Health & Science University
9:15 PM	Merck & Co., Inc.	Building a Healthy Diverse Workforce*	Digital Health Panel	Exelixis, Inc.	Synthetic Biology Panel	Dassault Systemes	Nurix Therapeutics, Inc.	Mirati Therapeutics	Surgery Partners Inc	TBD

Eastern Time	PRIVATE TRACK 1	PRIVATE TRACK 2	APAC & LatAm TRACK 1	APAC & LatAm TRACK 2
7:30 AM	Gennao Bio	Imcheck	J-Pharma Co., Ltd	RemeGen, Ltd.
8:00 AM	Quanta Dialysis Technologies	ITM	Wuxi Aptec Co Ltd	Mingmed Biotechnology Co., Ltd.
8:30 AM	SPT Labtech	RVHealth (Healthline)	Esco Lifesciences Group Ltd.	DXY
9:00 AM	Datavant, Inc.	Nimbus Therapeutics	Sosei Group Corporation	Ascentage Pharma
9:30 AM	Affinivax	ConcertAI	TBD	MicroPort Scientific Corporation
10:00 AM	TBD	Owkin	RIBOMIX Inc.	CanSino Biologics Inc
10:30 AM	BenevolentAI	Nuvaira	HEALIOS K.K.	Sinovac Biotech Ltd
11:00 AM	VillageMD	Elevate Bio	Modulus Discovery, Inc.	Chongqing Zhifei Biological Products Co Ltd
11:30 AM	ArsenalBio	Everlyhealth	Kyowa Kirin Co., Ltd.	ClouDr.
12:00 – 12:30 PM	Frontier Medicines	Waystar	BREAK	
12:30 – 1:25 PM	Keynote			
1:30 PM	Maze Therapeutics	Vital Connect, Inc.	Rakuten Medical, Inc.	TBD
2:00 PM	Viz.ai	DNAScript	Fujifilm Holdings Corporation	Medlinker
2:30 PM	CloudMed	RealMDx	Olympus Corporation	Jiangsu Hengrui Pharmaceuticals Co., Ltd.
3:00 PM	Laronde	BALT	Santen Pharmaceutical Company Ltd.	Abbisco Therapeutics
3:30 PM	Included Health	Atomwise Inc.	TBD	Hygeia Healthcare
4:00 PM	ST Genetics	Potrero Medical, Inc.	Shenzhen Mindray Bio-Medical Electronics Co Ltd	TBD
4:30 PM	Carbon Health	Shape Therapeutics	Akeso Biopharma, Inc.	Antengene Corporation
5:00 PM	Willow	SK Inc.	TBD	TBD
5:30 PM	Lexeo Therapeutics, Inc	IntelyCare	TBD	TBD

Public Company and Not-For-Profit sessions are 40 minutes inclusive of Q&A. There are no separate breakout sessions.
Private Company sessions are 25 minutes inclusive of Q&A. Emerging Markets sessions are 25 minutes and will not include Q&A.
Attendee question submission will be available through the 'Ask a Question' button on the Digital Conference Book.

*Building a Healthy Diverse Workforce and Retaining Top Talent For Now and the Future
**New Generation of Public & Population Health | New Role of Government in Healthcare

Full agenda – Day 2 (Tuesday)

TUESDAY, JANUARY 11 CONFERENCE AGENDA (as of 12.31.2021, subject to change)

Eastern Time	TRACK 1	TRACK 2	TRACK 3	TRACK 4	TRACK 5	TRACK 6	TRACK 7	TRACK 8	TRACK 9	NOT FOR PROFIT
7:30 AM	GlaxoSmithKline	Universal Health Services, Inc.	Sage Therapeutics	Sotera Health	Novocure	Nuvation Bio	Pulmonox Corporation	Scholar Rock	Coloplast A/S	TBD
8:15 AM	Endo International plc	CVS Health	Karuna Therapeutics	Thermo Fisher Scientific	Sophia Genetics	Amarin Corporation plc	Somalogic Inc.	SpringWorks Therapeutics	Progyny	Bon Secours Mercy Health
9:00 AM	Merck KGaA Darmstadt Germany (Healthcare)	McKesson Corporation	Abbott	Ortho Clinical Diagnostics	Kymera Therapeutics, Inc.	Almirall	Y-mAbs Therapeutics, Inc.	Rapt Therapeutics	Fresenius Medical Care	Spectrum Health
9:45 AM	Teva Pharmaceutical Industries Ltd.	Roche Group	BioNTech SE	Mettler-Toledo International, Inc.	Relay Therapeutics, Inc.	Zymeworks Inc.	Ambu A/S	IDEAYA Biosciences	Convey Health Solutions	Jefferson Health
10:30 AM	Elanco Animal Health Inc	Sanofi	ACADIA Pharmaceuticals Inc.	Charles River Laboratories	Akero Therapeutics	Cano Health	ALX Oncology	Day One Biopharmaceuticals, Inc	Avanos Medical	Indiana University Health
11:15 AM	ModivCare Inc.	Cigna	Amgen Inc.	PerkinElmer, Inc.	Danaher Corp.	Denali Therapeutics Inc.	Penumbra, Inc.	iTeos Therapeutics	Global Blood Therapeutics	Mass General Brigham
12:00 – 12:30 PM	BREAK								Last Mile of Healthcare	BREAK
12:30 – 1:25 PM	<p>Keynote: Improving the Quality and Accountability of Employer-Sponsored Healthcare Introduction: Peter Scher, Vice Chairman, JPMorgan Chase & Co. Panelists: Dan Mendelson, Chief Executive Officer, Morgan Health; Dr. Mark McClellan, MD, PhD, Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University; Andrew Bindman, M.D., wEVP and Chief Medical Officer, Kaiser Permanente; Moderated by: Bertha Coombs, CNBC Reporter</p>									
1:30 PM	Smith+Nephew	Establishment Labs	Sana Biotechnology, Inc.	Agilent Technologies Inc.	Century Therapeutics	Mirum Pharmaceuticals	iRhythm Technologies, Inc.	Vir Biotechnology	Hologic	City of Hope
2:15 PM	Heska	Walgreens Boots Alliance, Inc.	Legend Biotech Corporation	Myriad Genetics Inc.	Revolution Medicines	CooperCompanies	Becton, Dickinson and Company	Protagonist Therapeutics, Inc.	Butterfly Network, Inc.	Northwell Health
3:00 PM	Tenet Healthcare Corp.	Bright Health Group	Lyell Immunopharma, Inc.	Oxford Nanopore Technologies plc	Enanta Pharmaceuticals, Inc.	Nektar Therapeutics	Novanta Inc.	BioAtla	ORIC Pharmaceuticals	Prisma Health
3:45 PM	AbbVie	Vera	Allogene Therapeutics, Inc.	PHC Holdings Corporation	Berkeley Lights	Karyopharm Therapeutics Inc	CVRx	Annexon Biosciences	Health Catalyst	ProMedica Health System
4:30 PM	Eli Lilly and Co.	One Medical	Bio-Rad Laboratories	Labcorp	Akebia Therapeutics, Inc.	Siemens Healthineers	Teleflex Incorporated	Cytokinetics Inc	Premier Inc.	Mayo Clinic
5:15 PM	BeiGene Ltd	New Mega Opportunities in Healthcare*	Cue Health Inc.	AMN Healthcare	Monte Rosa Therapeutics, Inc.	Clover Health	Glaukos	Olema Oncology	Measuring What Works to Achieve Health Equity	TBD

*The New Mega Opportunities in Healthcare Will Be Enabled by Convergence Opportunities, Risks, and How to Capitalize

Eastern Time	PRIVATE TRACK 1	PRIVATE TRACK 2	APAC & LatAm TRACK 1	APAC & LatAm TRACK 2
7:30 AM	Theramex	AccentCare, Inc.	Shukun Technology	TBD
8:00 AM	Episcience Biopharma	TBD	Shanghai Junshi Biosciences	Hapvida Participações e Investimentos S.A.
8:30 AM	Sparing Vision	Elucida Oncology	Genscript Biotech Corporation	Rede D'or
9:00 AM	DiscGenics, Inc.	Dynacure	Sino Biopharmaceutical Ltd	RD
9:30 AM	TBD	Orca Bio	Regor Therapeutics	TBD
10:00 AM	TBD	Envirotainer	Reistone Biopharma	Fleury
10:30 AM	TBD	Noom	TBD	Oncoclinicas Do Brasil Servicos Medicos S.a.-Brazil
11:00 AM	Aledade	Rayze Bio	Innovent Biologics, Inc.	Blau Farmaceutica S/A
11:30 AM	Locana Bio	Caris Life Sciences	Shouti Pharma	Pague Menos
12:00 – 12:30 PM	StimLabs	Quell Tx	BREAK	
12:30 – 1:25 PM	Keynote			
1:30 PM	Help at Home	Korro Bio	Singleron Bio	Rede Mater Dei de Saude
2:00 PM	Boundless Bio	Senti Biosciences	Bioduro Sunda	Viveo
2:30 PM	TBD	Marengo Therapeutics	Wuhan Asia Heart Medical	Odontoprev Sa
3:00 PM	Neogene	Lyra Health	Tigermed / Frontage Holdings Corp	Kora Saude Participacoes S.A. - Brazil
3:30 PM	Aerin Medical Inc	TBD	Viva Biotech Holdings	Dasa
4:00 PM	TAG - The Aspen Group	TBD	Shanghai Microport Medbot (Group) Co Ltd	Genomma Lab Internacional SAB de CV
4:30 PM	Mammoth Biosciences	TBD	I-Mab Biopharma	TBD
5:00 PM	Precision Medicine Liquid Biopsy & Cancer Screening	Inception Fertility	TBD	TBD
5:30 PM		Garuda Therapeutics	TBD	TBD

Full agenda – Day 3 (Wednesday)

WEDNESDAY, JANUARY 12 CONFERENCE AGENDA (as of 12.31.2021, subject to change)

Eastern Time	TRACK 1	TRACK 2	TRACK 3	TRACK 4	TRACK 5	TRACK 6	TRACK 7	TRACK 8	TRACK 9	TRACK 10
7:30 AM	Vericel	TBD	Iovance Biotherapeutics, Inc.	ICON plc	Signify Health, Inc.	Ironwood Pharmaceuticals	Agios Pharmaceuticals, Inc.	Immunocore	Transmedics, Inc.	Atara Biotherapeutics
8:15 AM	Neogen Corp	Elekta AB	Ipsen	Invitae	Singular Genomics	Autolus	Generation Bio Co.	Rubius Therapeutics	Boston Scientific Corp.	TBD
8:00 AM	Bausch Health	Patterson Companies, Inc.	Lonza Group AG	Quest Diagnostics	Olink	Black Diamond Therapeutics, Inc.	Cryoport	ImmunoGen, Inc.	TBD	Genmab A/S
9:45 AM	WuXi Biologics	Henry Schein Inc	Clovis Oncology	Repligen	Pliant	Omeros	Elevation Oncology	Ionis Pharmaceuticals, Inc.	Inspire Medical Systems, Inc.	Hikma Pharmaceuticals
10:30 AM	IGM Biosciences	Covetrus, Inc.	Editas Medicine Inc	Syneos Health	Orasure Technologies, Inc	Pardes Biosciences, Inc	Aeglea BioTherapeutics	Lava Therapeutics	Inogen, Inc.	Idorsia Pharmaceuticals
11:15 AM	Amneal Pharmaceuticals	Aveanna Healthcare	Alkermes plc	Dentsply Sirona	Minerva Surgical	UCB SA	Nuvalent, Inc.	Amyris Inc	NeuroPace	Alcon
12:00 – 12:30 PM	BREAK									
12:30 – 1:25 PM	Keynote: Navigating Markets & Diversity <i>Panelists:</i> Jean Hynes, CEO, Wellington Management <i>Moderated by:</i> Julie Murphy, Healthcare Sector Specialist on the J.P. Morgan Trading Desk									
1:30 PM	Evolut Health	LifeSpan Health	Prometheus Biosciences	Quidel Corporation	ICU Medical, Inc.	Chinook Therapeutics	GI Therapeutics	Abiomed Inc.	LHC Group, Inc.	Apollo Medical
2:15 PM	Intellia Therapeutics, Inc.	Korlan	Dyne Therapeutics, Inc.	Renalytix	Precision Biosciences	Talaris Therapeutics	Cyteir Therapeutics Inc	Sharecare, Inc.	Revance Therapeutics, Inc	Morphic
3:00 PM	Inari	NuVasive, Inc.	Biomea Fusion	NanoString Technologies Inc	Myovant Sciences, Inc.	Mersana Therapeutics	CytomX Therapeutics, Inc.	OPKO Health, Inc.	NextGen Healthcare	Colfax
3:45 PM	Perrigo	Silk Road Medical, Inc.	bluebird bio, Inc.	Intuitive Surgical, Inc.	Precigen	Azenta	Amicus Therapeutics, Inc.	Ginkgo Bioworks	Amedisys Inc.	Repare
4:30 PM	HealthEquity, Inc.	Treace Medical Concepts, Inc.	Integra LifeSciences	Bio-Techne Corporation	Acadia Healthcare Company, Inc.	Crinetics Pharmaceuticals	ChemoCentryx, Inc.	Alignment Healthcare	Quantum-Si, Inc.	Eagle Pharmaceuticals
5:15 PM	MorphoSys	Bioventus	Samsung Biologics	Exact Sciences Corporation	Aligos Therapeutics	P3 Health	Oyster Point Pharma, Inc.	Innovage	MiMedx	Success in the "Health-First" Era: Safeguard Your Team & Maximize Performance*

*Success in the "Health-First" Era: Safeguard Your Team & Maximize Performance

Eastern Time	PRIVATE TRACK 1	PRIVATE TRACK 2	APAC & LatAm TRACK 1	APAC & LatAm TRACK 2
7:30 AM	Virgin Pulse	Carisma Therapeutics	Dr. Reddy's Laboratories Ltd	Belief Biomed Inc
8:00 AM	TBD	Strata Oncology, Inc.	Apollo Hospitals Enterprise Ltd	Grand Pharmaceutical Group Limited
8:30 AM	Scipher Medicine Corporation	Valo Health	Piramal Pharma Limited	TBD
9:00 AM	Aktis Oncology	ZocDoc	Cipla Ltd	EirGenx, Inc.
9:30 AM	Epirium Bio, Inc.	Palamedrix	TBD	Adimmune Corp
10:00 AM	Cityblock Health	TBD	Lupin Ltd	Oneness Biotech Co Ltd
10:30 AM	AavantBio	Advanced MedTech	Max Healthcare	Chime Biologics Limited
11:00 AM	Healx	TBD	New Frontier Health Corp	PharmaEssentia Corp
11:30 AM	LifePoint Health	Insitro	Lupeng Bio	TBD
12:00 – 12:30 PM	Dewpoint Therapeutics, Inc.	TBD	BREAK	
12:30 – 1:25 PM	Keynote			
1:30 PM	Spring Health	Nikang Therapeutics	Shanghai Fosun Pharmaceutical (Group) Co	TBD
2:00 PM	TBD	TBD	Kintor Pharmaceutical Limited	IHH Healthcare Bhd
2:30 PM	TBD	TBD	Icon Group	TBD
3:00 PM	Intervenn	Transcarent	harrison.ai	Seegene, Inc.
3:30 PM	Asher Biotherapeutics Inc	OnPoint Surgical	Paradigm Biopharmaceuticals Ltd	Hanmi Pharmaceutical Co Ltd
4:00 PM	Tebra	TBD	Metro Pacific Hospitals Holdings Inc	HK innO. N Corp
4:30 PM	TBD	Bluestar Genomics	MIRXES Pte Ltd.	LG Chem Ltd
5:00 PM	Crossover Health	TBD	TBD	TBD
5:30 PM	TBD	TBD	TBD	TBD

Full agenda – Day 4 (Thursday)

THURSDAY, JANUARY 13 CONFERENCE AGENDA *(as of 12.31.2021, subject to change)*

Eastern Time	TRACK 1	TRACK 2	TRACK 3	TRACK 4	TRACK 5	TRACK 6	TRACK 7	TRACK 8	TRACK 9
7:30 AM	TBD	Harmony Biosciences	TBD	Adagio	Kala Pharmaceuticals, Inc	Tivity Health, Inc.	Infinity Pharmaceuticals, Inc.	Molecular Partners	Humanigen
8:15 AM	Rapid Micro Biosystems	Quanterix Corporation	Galapagos NV	TBD	Marinus Pharmaceuticals, Inc.	Gritstone bio, Inc	AnaptysBio, Inc.	Anavex Life Sciences	Achilles Therapeutics plc
9:00 AM	Akoya Biosciences, Inc.	Taysha Gene Therapies, Inc	Orchard Therapeutics	Landos Biopharma	Asensus Surgical	Leap Therapeutics Inc	Solid Biosciences, Llc	GN Store Nord	Surrozen, Inc.
9:45 AM	Accelerate Diagnostics Inc	Urogen Pharma	Aurinia Pharmaceuticals Inc.	Magenta Therapeutics	RxSight, Inc.	Immunovant	Caribou Biosciences, Inc.	Bioxel Therapeutics, Inc.	TBD
10:30 AM	Zymergen	NGM Biopharmaceuticals, Inc.	Esperion Therapeutics, Inc	Lexicon Pharmaceuticals, Inc.	Tricida, Inc.	Viewray, Inc.	Frequency Therapeutics	Affimed	Freeline Therapeutics
11:15 AM	Sutro Biopharma	Rallybio Corporation	Talkspace	Aprea Therapeutics	Inventiva	Rain Therapeutics	InflaRx N.V.	Shattuck Labs	Terns Pharmaceuticals, Inc.
12:00 PM	Pacific Biosciences	Jounce Therapeutics, Inc.	Alpine Immune Sciences	Fulcrum Therapeutics	Aptinyx Inc.	GoodRx	Theravance Biopharma Inc	Abivax	Caremax, Inc.
Conference Conclusion									

Eastern Time	PRIVATE TRACK 1	PRIVATE TRACK 2
7:30 AM	TBD	Kry
8:00 AM	Ardent Health Services	TBD
8:30 AM	Heartflow, Inc.	TBD
9:00 AM	TBD	TBD
9:30 AM	TBD	TBD
10:00 AM	Aardvark Therapeutics Inc	TBD
10:30 AM	TBD	TBD
11:00 AM	TBD	TBD
11:30 AM	TBD	TBD
Conference Conclusion		